Entrada Therapeutics, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021, with comparison to 2020. This is an annual filing, not a standalone fourth-quarter report. The company is a preclinical-stage biotechnology company developing its Endosomal Escape Vehicle (EEV) intracellular-delivery platform; it had not initiated clinical trials or generated product revenue.
Financial performance and position
| Metric | 2021 | 2020 | Change / context |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue; none expected in the foreseeable future. |
| Research and development expense | $35.9 million | $21.1 million | Increased $14.8 million, approximately 70%, primarily from personnel, facilities, outside research and lab supplies. |
| General and administrative expense | $15.2 million | $5.6 million | Increased $9.6 million, approximately 173%, including personnel, professional services and public-company costs. |
| Total operating expenses | $51.1 million | $26.7 million | Increased $24.5 million, approximately 92%. |
| Net loss | $51.2 million | $26.5 million | Loss widened by $24.6 million; accumulated deficit was $93.7 million at year-end. |
| Net loss per share, basic and diluted | $8.16 | $24.00 | Per-share comparison is affected by the IPO and change in weighted-average shares. |
| Net cash used in operating activities | $50.9 million | $25.6 million | Operating cash use approximately doubled. |
| Net cash used in investing activities | $4.6 million | $2.3 million | Primarily purchases of property and equipment. |
| Cash and cash equivalents | $291.1 million | $39.0 million | Year-end 2021 balance included $190.7 million of net IPO proceeds and $115.8 million of net Series B proceeds during 2021. |
| Total assets / current liabilities | $305.8 million / $6.7 million | $43.5 million / $3.4 million | Year-end 2021 stockholders’ equity was $298.7 million. |
Margins: Not meaningful because the company had no revenue. Debt: The filing does not report borrowings or a debt balance. It reports $16.9 million of operating lease commitments, principally due in 2022 and 2023; the lease had an option to terminate after November 30, 2023 without penalty.
Ernst & Young issued an unqualified opinion on the consolidated financial statements. Management concluded disclosure controls and procedures were effective at the reasonable-assurance level; the company was exempt from auditor attestation of internal control over financial reporting as an emerging growth company.
Business developments and outlook
- In November 2021, Entrada completed its IPO, issuing 10.4 million shares at $20 per share and receiving approximately $190.7 million in net proceeds. Preferred stock converted into common stock upon the IPO. The company reported no material change in the planned use of IPO proceeds.
- Management estimated that year-end cash and cash equivalents would fund operations and capital expenditures into the second half of 2024. This is a forecast based on assumptions, not a guarantee; the company expects to need additional financing to advance its strategy.
- Lead candidate ENTR-601-44 targets exon 44-amenable Duchenne muscular dystrophy (DMD). The company planned to submit an IND in the second half of 2022, subject to completing IND-enabling work, and anticipated initial clinical data in 2023 if authorized to proceed.
- The DM1 program was expected to have a candidate and supporting data announced in early 2022, with an IND submission planned for 2023. Management also planned to select an exon 45 DMD candidate in 2022 and a Pompe disease candidate by the end of 2023.
- Programs in immunology and oncology remained preclinical or in discovery. Management anticipated 2022 proof-of-concept work for IRF5 and oncology programs; potential candidate selection was discussed for 2023. These are plans, not reported clinical outcomes.
- Management had deprioritized ENTR-501, an enzyme-replacement program for MNGIE, to focus resources on oligonucleotide programs and was exploring partnership options to advance it.
Principal risks and contingencies
- The EEV platform and candidates are unproven in humans; all programs were preclinical or in discovery, and the company had not initiated clinical trials. Preclinical findings may not predict clinical safety or efficacy.
- The company expects continued operating losses and negative operating cash flows. It may need additional capital earlier than projected; unavailable or unfavorable financing could force delays, reductions or termination of programs.
- Development depends substantially on ENTR-601-44 and faces regulatory, manufacturing, supply, clinical-enrollment, safety, efficacy and commercialization risks. Entrada relies on third parties for manufacturing and research services.
- Competition is significant, including existing DMD exon-skipping therapies and other programs in development. Patent protection, third-party intellectual property rights and license obligations also pose risks.
- COVID-19 had caused temporary operational reductions that the company said had normalized; it reported no significant financial impact or asset impairment to date, but future effects remained uncertain.
- No legal proceedings were reported as probable to have a material adverse effect at year-end. Potential license milestones, royalties and sublicense payments are not included in the lease-obligation table and were not considered probable at year-end.
Investor facts to verify
- Actual cash use, financing needs and runway versus management’s estimate through the second half of 2024.
- Completion and results of ENTR-601-44 IND-enabling studies, FDA response to any IND, and whether clinical initiation and 2023 data targets remain achievable.
- Whether reported preclinical findings translate into human safety, target engagement, dystrophin production and meaningful clinical benefit.
- Progress on DM1, exon 45 DMD, Pompe, IRF5 and oncology milestones, including whether candidate-selection and IND timelines have changed.
- Manufacturing readiness, third-party supplier capacity, lease commitments, and any material changes to license costs or obligations.